An Observational Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Oct 2018
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms APOLO
- Sponsors Celgene Corporation
- 04 Oct 2018 Planned End Date changed from 30 Jun 2018 to 31 Dec 2018.
- 04 Oct 2018 Planned primary completion date changed from 30 Jun 2018 to 31 Dec 2018.
- 04 Oct 2018 Status changed from recruiting to active, no longer recruiting.